{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:20:39Z","timestamp":1793906439752,"version":"4.8.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Breast cancer (BC) is the most common cancer among women worldwide, with 2.3 million new cases and 685\u00a0000 deaths annually. It has the highest incidence in North America, Europe, and Australia and lower rates in parts of Asia and Africa. Risk factors include age, family history, hormone replacement therapy, obesity, alcohol consumption, and lack of physical activity. BRCA1 and BRCA2 gene mutations significantly increase the risk. The 5-year survival rate is over 90% in developed countries but lower in developing ones. Early screening and diagnosis, using mammography and MRI, are crucial for reducing mortality. In recent years, significant progress has been made in studying BC immunophenotyping, particularly in multicolor flow cytometry, molecular imaging techniques, and tumor microenvironment analysis. These technologies improve diagnosis, classification, and detection of minimal residual disease. Novel immunotherapies targeting the tumor microenvironment, like CAR-T cell therapy, show high efficiency and fewer side effects. High levels of tumor-infiltrating lymphocytes correlate with better prognosis, while immune checkpoint molecules (PD-1, PD-L1) help cancer cells evade the immune system. Tumor-associated macrophages promote invasion and metastasis. Blocking molecules like CTLA-4, LAG-3, and TIM-3 enhance antitumor responses, and cytokines like IL-10 and TGF-\u03b2 aid tumor growth and immune evasion. Mendelian randomization (MR) studies use genetic variants to reduce confounding bias and avoid reverse causation, providing robust causal inferences about immune cell phenotypes and BC. This approach supports the development of precision medicine and personalized treatment strategies for BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This study aims to conduct MR analysis on 731 immune cell phenotypes with BC in the BCAC and Finngen R10 datasets, followed by a meta-analysis of the primary results using the inverse-variance weighted (IVW) method and multiple corrections for the significance\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -values from the meta-analysis. Specifically, the study is divided into three parts: First, data on 731 immune cell phenotypes and BC are obtained and preprocessed from the GWAS Catalog and Open GWAS (BCAC) and the Finngen R10 databases. Second, MR analysis is performed on the 731 immune cell phenotypes with BC data from the BCAC and Finngen R10 databases, followed by a meta-analysis of the primary results using the IVW method, with multiple corrections for the significance\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -values from the meta-analysis. Finally, the positively identified immune cell phenotypes are used as outcome variables, and BC as the exposure variable for reverse MR validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study found that two immune phenotypes exhibited strong significant associations in MR analysis combined with meta-analysis and multiple corrections. For the immune phenotype CD3 on CD28+ CD4-CD8- T cells, the results were as follows: in the BCAC dataset, the IVW result was odds ratio (OR) = 0.942 (95% CI: 0.915\u20130.970,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =6.76\u00d710\n                      <jats:sup>-5<\/jats:sup>\n                      ),\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.059; MR Egger result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.095; and the weighted median result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.060. In the Finngen R10 dataset, the IVW result was OR=0.956 (95% CI: 0.907\u20131.01,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.092),\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.045; MR Egger result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.070; and weighted median result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.035. The\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      values were consistent in direction across all three MR methods in both datasets. The meta-analysis of the IVW results from both datasets showed OR=0.945 (95% CI: 0.922\u20130.970,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =1.70\u00d710\n                      <jats:sup>-5<\/jats:sup>\n                      ). After Bonferroni correction, the significant\n                      <jats:italic toggle=\"yes\">P-<\/jats:italic>\n                      value was\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.01, confirming the immune phenotype as a protective factor against BC. For the immune phenotype HLA DR on CD33- HLA DR+, the results were as follows: in the BCAC dataset, the IVW result was OR=0.977 (95% CI: 0.964\u20130.990,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =7.64\u00d710\n                      <jats:sup>-4<\/jats:sup>\n                      ),\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.023; MR Egger result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.016; and the weighted median result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.019. In the Finngen R10 dataset, the IVW result was OR=0.960 (95% CI: 0.938\u20130.983,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =6.51\u00d710\n                      <jats:sup>-4<\/jats:sup>\n                      ),\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.041; MR Egger result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.064; and weighted median result was\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      =\u22120.058. The\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      values were consistent in direction across all three MR methods in both datasets. The meta-analysis of the IVW results from both datasets showed OR=0.973 (95% CI: 0.961\u20130.984,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =3.80\u00d710\n                      <jats:sup>-6<\/jats:sup>\n                      ). After Bonferroni correction, the significant\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value was\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.003, confirming this immune phenotype as a protective factor against BC. When the immune cell phenotypes CD3 on CD28+ CD4-CD8- T cells and HLA DR on CD33- HLA DR+ were used as outcomes and BC was used as exposure, the data processing and analysis procedures were the same. The MR analysis results are as follows: data from the FinnGen database regarding the effect of positive immune phenotypes on malignant neoplasm of the breast indicated a\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      coefficient of \u22120.011, OR = 0.99 (95% CI: \u22120.117\u20130.096,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.846); data from the BCAC database regarding favorable immune phenotypes for BC demonstrated a\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      coefficient of \u22120.052, OR=0.095 (95% CI: \u22120.144\u20130.040,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.266). The results suggest insufficient evidence in both databases to indicate that BC inversely affects these two immune cell phenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Evidence suggests that the immune cell phenotypes CD3 on CD28+ CD4-CD8- T cells and HLA DR on CD33- HLA DR+ protect against BC. This protective effect may be achieved through various mechanisms, including enhancing immune surveillance to recognize and eliminate tumor cells; secreting cytokines to inhibit tumor cell proliferation and growth directly; triggering apoptotic pathways in tumor cells to reduce their number; modulating the tumor microenvironment to make it unfavorable for tumor growth and spread; activating other immune cells to boost the overall immune response; and inhibiting angiogenesis to reduce the tumor\u2019s nutrient supply. These mechanisms work together to help protect BC patients and slow disease progression. Both immune cell phenotypes are protective factors for BC patients and can be targeted to enhance their function and related pathways for BC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000001840","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:33:23Z","timestamp":1719509603000},"page":"230-241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["The association between immune cells and breast cancer: insights from Mendelian randomization and meta\u2010analysis"],"prefix":"10.1097","volume":"111","author":[{"given":"Wanxian","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, First People\u2019s Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Panglong District, Kunming, Yunnan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Animal Science of Fudan University, Xuhui District, Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, First People\u2019s Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Panglong District, Kunming, Yunnan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20260304","first-page":"289","article-title":"Self-examination of breasts as an element of BC prophylaxis","volume":"59","author":"Domza LDR","year":"2004","journal-title":"Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"672350","DOI":"10.3389\/fendo.2021.672350","article-title":"Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019","volume":"12","author":"Deng","year":"2021","journal-title":"Front Endocrinol"},{"key":"R3-20260304","first-page":"1321","article-title":"The importance of early detection concerning treatment of cancer of the female breast (author\u2019s transl)","volume":"104","author":"Widow","year":"1979","journal-title":"Zentralbl Chir"},{"key":"R4-20260304","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.3390\/cancers13164233","article-title":"Tumor microenvironment in BC-updates on therapeutic implications and pathologic assessment","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41597-023-02032-2","article-title":"Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in BC","volume":"10","author":"Zhao","year":"2023","journal-title":"Sci Data"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"a040980","DOI":"10.1101\/cshperspect.a040980","article-title":"Using Mendelian randomization to improve the design of randomized trials","volume":"11","author":"Ference","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s40471-018-0144-1","article-title":"Mendelian randomization studies of cancer risk: a literature review","volume":"5","author":"Pierce","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"1193357","DOI":"10.3389\/fimmu.2023.1193357","article-title":"Serum DKK-1 level in ankylosing spondylitis: insights from meta-analysis and Mendelian randomization","volume":"14","author":"Fang","year":"2023","journal-title":"Front Immunol"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/clinchem\/hvac209","article-title":"Sex hormone-binding globulin and risk of coronary heart disease in men and women","volume":"69","author":"Li","year":"2023","journal-title":"Clin Chem"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12888-023-05081-4","article-title":"Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Psychiatry"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jacc.2020.10.048","article-title":"Diet-derived circulating antioxidants and risk of coronary heart disease: a Mendelian randomization study","volume":"77","author":"Luo","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new BC risk loci","volume":"551","author":"Michailidou","year":"2017","journal-title":"Nature"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.joca.2021.08.003","article-title":"The causal role of gut microbiota in development of osteoarthritis","volume":"29","author":"Yu","year":"2021","journal-title":"Osteoarthritis Cartilage"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2105-12-231","article-title":"Estimation of allele frequency and association mapping using next-generation sequencing data","volume":"12","author":"Kim","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"R18-20260304","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"1285274","DOI":"10.3389\/fgene.2023.1285274","article-title":"A two-sample Mendelian randomization analysis: causal association between chemokines and pan-carcinoma","volume":"14","author":"Cui","year":"2023","journal-title":"Front Genet"},{"key":"R20-20260304","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrg1123","article-title":"Haplotype blocks and linkage disequilibrium in the human genome","volume":"4","author":"Wall","year":"2003","journal-title":"Nat Rev Genet"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrg2361","article-title":"Linkage disequilibrium--understanding the evolutionary past and mapping the medical future","volume":"9","author":"Slatkin","year":"2008","journal-title":"Nat Rev Genet"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"695480","DOI":"10.3389\/fcvm.2021.695480","article-title":"Using a two-sample Mendelian Randomization method in assessing the causal relationships between human blood metabolites and heart failure","volume":"8","author":"Wang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"12976","DOI":"10.1038\/s41598-022-17207-x","article-title":"Using a two-sample mendelian randomization analysis to explore the relationship between physical activity and Alzheimer\u2019s disease","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1177\/0962280215597579","article-title":"A review of instrumental variable estimators for Mendelian randomization","volume":"26","author":"Burgess","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"R25-20260304","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12890-023-02788-8","article-title":"Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Pulm Med"},{"key":"R26-20260304","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed)"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jama.2018.6971","article-title":"Odds ratios-current best practice and use","volume":"320","author":"Norton","year":"2018","journal-title":"JAMA"},{"key":"R29-20260304","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13059-019-1716-1","article-title":"A practical guide to methods controlling false discoveries in computational biology","volume":"20","author":"Korthauer","year":"2019","journal-title":"Genome Biol"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-61779-870-2_13","article-title":"Multiple testing in large-scale genetic studies","volume":"888","author":"Bouaziz","year":"2012","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp Mol Med"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2767-9764.CRC-21-0154","article-title":"A TCR-like CAR promotes sensitive antigen recognition and controlled T-cell expansion upon mRNA vaccination","volume":"2","author":"Birtel","year":"2022","journal-title":"Cancer Res Comm"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"2220839","DOI":"10.1080\/19420862.2023.2220839","article-title":"Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties","volume":"15","author":"Elsayed","year":"2023","journal-title":"Mabs"},{"key":"R34-20260304","doi-asserted-by":"crossref","first-page":"eabn1082","DOI":"10.1126\/scitranslmed.abn1082","article-title":"CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models","volume":"14","author":"Wei","year":"2022","journal-title":"Sci Transl Med"},{"key":"R35-20260304","doi-asserted-by":"crossref","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"R36-20260304","doi-asserted-by":"crossref","first-page":"eaba2325.","DOI":"10.1126\/scitranslmed.aba2325","article-title":"Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy","volume":"12","author":"Waite","year":"2020","journal-title":"Sci Transl Med"},{"key":"R37-20260304","doi-asserted-by":"crossref","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","article-title":"CD3(+)CD4(-)CD8(-) (Double-Negative) T cells in inflammation, immune disorders and cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"R38-20260304","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0165-2427(99)00118-X","article-title":"Extrathymic CD4\/CD8 double positive T cells","volume":"72","author":"Zuckermann","year":"1999","journal-title":"Vet Immunol Immunopathol"},{"key":"R39-20260304","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1189\/jlb.1RU0814-382","article-title":"CD4+\/CD8+ double-positive T cells: more than just a developmental stage?","volume":"97","author":"Overgaard","year":"2015","journal-title":"J Leukoc Biol"},{"key":"R40-20260304","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1038\/s41388-021-01896-1","article-title":"Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative BC","volume":"40","author":"Qiu","year":"2021","journal-title":"Oncogene"},{"key":"R41-20260304","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"R42-20260304","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R43-20260304","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"R44-20260304","first-page":"008","article-title":"Anti-PD-1 And Anti-PD-L1 antibodies as immunotherapy against cancer: a structural perspective","volume":"73","author":"C\u00f3rdova-Bahena","year":"2020","journal-title":"Rev Invest Clin"},{"key":"R45-20260304","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/s41598-017-14417-6","article-title":"Combined immunotherapy with anti-PDL-1\/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma","volume":"7","author":"Rigo","year":"2017","journal-title":"Sci Rep"},{"key":"R46-20260304","doi-asserted-by":"crossref","first-page":"1125876","DOI":"10.3389\/fimmu.2023.1125876","article-title":"Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1\/PD-L1 inhibitors in cancer patients","volume":"14","author":"Geng","year":"2023","journal-title":"Front Immunol"},{"key":"R47-20260304","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1038\/s41598-021-93807-3","article-title":"HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior","volume":"11","author":"Senosain","year":"2021","journal-title":"Sci Rep"},{"key":"R48-20260304","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3390\/cancers14092260","article-title":"HLA-DR presentation of the tumor antigen MSLN associates with clinical outcome of ovarian cancer patients","volume":"14","author":"Tegeler","year":"2022","journal-title":"Cancers"},{"key":"R49-20260304","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/eji.202149735","article-title":"Flow cytometry-based high-throughput RNAi screening for miRNAs regulating MHC class II HLA-DR surface expression","volume":"52","author":"Houseman","year":"2022","journal-title":"Eur J Immunol"},{"key":"R50-20260304","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.carres.2008.01.009","article-title":"CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease","volume":"343","author":"McMillan","year":"2008","journal-title":"Carbohydr Res"},{"key":"R51-20260304","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"L\u00e4ubli","year":"2020","journal-title":"Cellul Mol Life Sci CMLS"},{"key":"R52-20260304","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"R53-20260304","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","article-title":"Clinical significance of circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma treated with ipilimumab","volume":"22","author":"Sade-Feldman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R54-20260304","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"De Propris","year":"2011","journal-title":"Haematologica"},{"key":"R55-20260304","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","article-title":"Natural regulatory T cells: mechanisms of suppression","volume":"13","author":"Miyara","year":"2007","journal-title":"Trends Mol Med"},{"key":"R56-20260304","doi-asserted-by":"crossref","first-page":"793234","DOI":"10.3389\/fimmu.2022.793234","article-title":"Autoimmunity and cancer-two sides of the same coin","volume":"13","author":"Sakowska","year":"2022","journal-title":"Front Immunol"},{"key":"R57-20260304","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R58-20260304","first-page":"77","article-title":"Innate and adaptive immune cells in tumor microenvironment","volume":"1","author":"GS","year":"2021","journal-title":"Gulf J Oncol"},{"key":"R59-20260304","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.4049\/jimmunol.150.6.2554","article-title":"Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression","volume":"150","author":"Weller","year":"1993","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"key":"R60-20260304","first-page":"378","article-title":"[Immunophenotypic features of acute myeloid leukemia with AML-1\/ETO fusion gene]","volume":"15","author":"Zhang","year":"2007","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:06:54Z","timestamp":1772626014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001840","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"2024-03-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}